$KALV
KalVista Pharmaceuticals, Inc. Stock $kalv

$kalv Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-K Financial Statement

#000156459021036441 Filed on July 13, 2021

Income Statement

Concept	2021 Q3	2021	2020 Q2
Revenue	$0.00	$0.00	$3.824M
YoY Change		-100.0%	30.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.847M	$16.64M	$3.300M
YoY Change	78.26%	27.68%	8.2%
% of Gross Profit
Research & Development	$13.67M	$41.29M	$9.490M
YoY Change	22.37%	2.72%	-14.81%
% of Gross Profit
Depreciation & Amortization	$132.0K	$500.0K	$130.0K
YoY Change	3.13%	-2.34%	8.33%
% of Gross Profit
Operating Expenses	$19.52M	$57.92M	$12.78M
YoY Change	35.15%	8.83%	-9.9%
Operating Profit	-$19.52M	-$57.92M
YoY Change		42.9%
Interest Expense	$223.0K	$1.950M	-$250.0K
YoY Change	-68.14%	10.8%	-171.43%
% of Operating Profit
Other Income/Expense, Net	$3.184M	$11.68M	$2.500M
YoY Change	8.67%	3.42%	-0.4%
Pretax Income	-$16.11M	-$46.24M	-$6.710M
YoY Change	49.02%	58.15%	-20.12%
Income Tax		$0.00	-$120.0K
% Of Pretax Income
Net Earnings	-$16.11M	-$46.24M	-$6.585M
YoY Change	48.96%	58.83%	-22.77%
Net Earnings / Revenue			-172.2%
Basic Earnings Per Share	-$0.66	-$2.42
Diluted Earnings Per Share	-$659.4K	-$2.42	-$368.8K
COMMON SHARES
Basic Shares Outstanding	24.44M	19.09M	17.85M
Diluted Shares Outstanding	24.43M	19.09M

Balance Sheet

Concept	2021 Q3	2021	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$230.6M	$248.9M	$67.71M
YoY Change	258.68%	267.69%	-32.83%
Cash & Equivalents	$48.34M	$50.59M	$15.79M
Short-Term Investments	$182.3M	$198.3M	$51.93M
Other Short-Term Assets	$5.538M	$4.917M	$4.500M
YoY Change	67.82%	9.27%	32.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$249.8M	$264.3M	$88.70M
YoY Change	211.45%	197.93%	-23.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.151M	$7.549M	$2.043M
YoY Change	161.46%	104.03%	-15.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$178.0K
YoY Change	0.0%	0.0%	2.89%
Total Long-Term Assets	$9.351M	$7.749M	$3.833M
YoY Change	152.59%	103.92%	48.22%
TOTAL ASSETS
Total Short-Term Assets	$249.8M	$264.3M	$88.70M
Total Long-Term Assets	$9.351M	$7.749M	$3.833M
Total Assets	$259.1M	$272.0M	$92.53M
YoY Change	208.85%	194.07%	-21.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.448M	$1.981M	$1.677M
YoY Change	-19.56%	16.53%	-41.36%
Accrued Expenses	$5.876M	$7.793M	$5.455M
YoY Change	-12.3%	29.88%	-3.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.229M	$9.774M	$7.720M
YoY Change	-3.19%	26.94%	-57.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.474M	$5.046M	$1.100M
YoY Change	547.4%	358.73%	-66.67%
Total Long-Term Liabilities	$6.474M	$5.046M	$1.057M
YoY Change	547.4%	358.73%	-68.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.229M	$9.774M	$7.720M
Total Long-Term Liabilities	$6.474M	$5.046M	$1.057M
Total Liabilities	$14.70M	$14.82M	$8.777M
YoY Change	54.77%	68.41%	-58.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$183.9M		-$121.6M
YoY Change			31.48%
Common Stock			$207.2M
YoY Change			8.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$244.4M	$257.2M	$83.75M
YoY Change
Total Liabilities & Shareholders Equity	$259.1M	$272.0M	$92.53M
YoY Change	208.86%	194.07%	-21.67%

Cashflow Statement

Concept	2021 Q3	2021	2020 Q2
OPERATING ACTIVITIES
Net Income	-$16.11M	-$46.24M	-$6.585M
YoY Change	48.96%	58.83%	-22.77%
Depreciation, Depletion And Amortization	$132.0K	$500.0K	$130.0K
YoY Change	3.13%	-2.34%	8.33%
Cash From Operating Activities	-$17.74M	-$30.17M	-$12.62M
YoY Change	394.29%	-32.68%	19.96%
INVESTING ACTIVITIES
Capital Expenditures	$287.0K	$82.00K	-$10.00K
YoY Change	1204.55%	-62.73%	-96.3%
Acquisitions
YoY Change
Other Investing Activities	$15.17M	-$147.6M	$10.03M
YoY Change	173.79%	-969.61%	-172.84%
Cash From Investing Activities	$14.88M	-$147.7M	$10.02M
YoY Change	169.93%	-981.36%	-171.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$210.6M
YoY Change		1743.65%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	608.0K	212.1M	0.000
YoY Change	1221.74%	1731.12%	-100.0%
NET CHANGE
Cash From Operating Activities	-17.74M	-30.17M	-12.62M
Cash From Investing Activities	14.88M	-147.7M	10.02M
Cash From Financing Activities	608.0K	212.1M	0.000
Net Change In Cash	-2.249M	34.80M	-2.600M
YoY Change	-201.08%	-314.61%	-89.35%
FREE CASH FLOW
Cash From Operating Activities	-$17.74M	-$30.17M	-$12.62M
Capital Expenditures	$287.0K	$82.00K	-$10.00K
Free Cash Flow	-$18.02M	-$30.25M	-$12.61M
YoY Change	399.22%	-32.82%	23.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24436492
CY2020Q4	dei	Entity Public Float EntityPublicFloat	282204641
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15789000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	51925000
CY2020Q2	kalv	Research And Development Tax Credits Receivable ResearchAndDevelopmentTaxCreditsReceivable	16527000
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4455000
CY2020Q2	us-gaap	Assets Current AssetsCurrent	88696000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2043000
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5758000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1612000
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	200000
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	178000
CY2021Q2	us-gaap	Assets Assets	272013000
CY2020Q2	us-gaap	Assets Assets	92529000
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1981000
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1677000
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6930000
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5455000
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	863000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	588000
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9774000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7720000
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5046000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1057000
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5046000
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1057000
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	24000
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	18000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	426437000
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	207208000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167836000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121592000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1432000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1882000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	257193000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	83752000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	272013000
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	92529000
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24422531
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17845599
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24422531
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17845599
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9128000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20692000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124000
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	153000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	300000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	450000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	44000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45794000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29072000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21633000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.42
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.64
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19094440
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17748666
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15080863
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	27253000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	87910000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	242000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2966000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11422000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	216000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4448000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	208934000
CY2021	kalv	Stock Issued During Period Value At Market Sales Agreement Net Of Issuance Costs StockIssuedDuringPeriodValueAtMarketSalesAgreementNetOfIssuanceCosts	1648000
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1535000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7118000
CY2020	kalv	Stock Issuance Costs StockIssuanceCosts	123000
CY2021	kalv	Stock Issuance Costs StockIssuanceCosts	239000
CY2021	us-gaap	Profit Loss ProfitLoss	-46244000
CY2020	us-gaap	Profit Loss ProfitLoss	-29116000
CY2019	us-gaap	Profit Loss ProfitLoss	-20816000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	537000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	512000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	378000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7118000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4448000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2966000
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	153000
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	300000
CY2019	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	23000
CY2021	kalv	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	114000
CY2020	kalv	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	13000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	685000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	193000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	574000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-74000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	80000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1112000
CY2021	kalv	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-7457000
CY2020	kalv	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	5781000
CY2019	kalv	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	4883000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	222000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1979000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	22000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	150000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1004000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1534000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	983000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-48000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2665000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12690000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-16127000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30171000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44816000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	201210000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49797000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	79889000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	53638000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	66770000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11548000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	220000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1081000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-147654000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16753000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-69422000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	210582000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1535000
CY2019	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	209000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11584000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87943000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	511000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	262000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1205000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34803000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16217000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19049000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15789000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32006000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51055000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50592000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4784000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	309000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of estimates: <font style="font-weight:normal;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</font></p>
CY2021Q2	kalv	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	248900000
CY2017Q4	kalv	Number Of Performance Obligations NumberOfPerformanceObligations	2
CY2021	kalv	Agreement Expiration Date AgreementExpirationDate	2020-02-10
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2985000
CY2021Q2	kalv	Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure	201322000
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	650000
CY2020Q2	kalv	Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure	52575000
CY2021Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	198536000
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	62000
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	261000
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	198337000
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	51456000
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	470000
CY2021Q2	kalv	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	50542000
CY2021Q2	kalv	Available For Sale Securities Debt Maturities After Two Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughFiveYearsFairValue	18560000
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3880000
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3411000
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2089000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1368000
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	51925000
CY2021Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	129235000
CY2021Q2	kalv	Accrued Research Expense Current AccruedResearchExpenseCurrent	2476000
CY2020Q2	kalv	Accrued Research Expense Current AccruedResearchExpenseCurrent	2821000
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3507000
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2333000
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	557000
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	173000
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	390000
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	128000
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6181250
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	36.00
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	806250
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	209200000
CY2021	kalv	Number Of Equity Based Compensation Plans NumberOfEquityBasedCompensationPlans	3
CY2021	kalv	Number Of Legacy Plans NumberOfLegacyPlans	2
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0047
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0206
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0290
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.817
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.811
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.772
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2300677
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	246575
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	835500
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	53004
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2836598
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1446403
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2836598
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.27
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.71
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.82
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.85
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.22
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.40
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	13.22
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M29D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M23D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4899
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33514
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19661
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	33514
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.24
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.76
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.62
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4200000000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	431000000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	950000000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1535000000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	242000000
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	13000000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
CY2021Q2	kalv	Contractual Obligation Remaining Commitment Including Cancellation Provisions ContractualObligationRemainingCommitmentIncludingCancellationProvisions	32200000
CY2021	kalv	Amount Associated With Indemnification AmountAssociatedWithIndemnification	0
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	926000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	743000
CY2020	kalv	Finance Lease Costs FinanceLeaseCosts	54000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	149000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	47000
CY2021	us-gaap	Lease Cost LeaseCost	1088000
CY2020	us-gaap	Lease Cost LeaseCost	857000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1310000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1107000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	971000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	991000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1012000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2470000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7861000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1952000
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5909000
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	696000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	708000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	54000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10909000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-6337000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5006000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-35335000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22903000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-15686000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-46244000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-29240000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20692000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.016
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.016
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.083
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.121
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.059
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.009
CY2019	kalv	Effective Income Tax Rate Reconciliation Global Intangible Low Taxed Income EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome	-0.076
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.115
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.066
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.063
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.006
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14410000
CY2020Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7367000
CY2021Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2620000
CY2020Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2162000
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17030000
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9529000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7500000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1100000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1600000

Files In Submission

Name	View Source	Status
0001564590-21-036441-index-headers.html	Edgar Link	pending
0001564590-21-036441-index.html	Edgar Link	pending
0001564590-21-036441.txt	Edgar Link	pending
0001564590-21-036441-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gk5g4onp2lz3000001.jpg	Edgar Link	pending
gk5g4onp2lz3000002.jpg	Edgar Link	pending
gk5g4onp2lz3000003.jpg	Edgar Link	pending
gk5g4onp2lz3000004.jpg	Edgar Link	pending
gk5g4onp2lz3000005.jpg	Edgar Link	pending
gk5g4onp2lz3000006.jpg	Edgar Link	pending
gptjcpbswis2000001.jpg	Edgar Link	pending
kalv-10k_20210430.htm	Edgar Link	pending
kalv-20210430.xml	Edgar Link	completed
kalv-20210430.xsd	Edgar Link	pending
kalv-20210430_cal.xml	Edgar Link	unprocessable
kalv-20210430_def.xml	Edgar Link	unprocessable
kalv-20210430_lab.xml	Edgar Link	unprocessable
kalv-20210430_pre.xml	Edgar Link	unprocessable
kalv-ex1018_356.htm	Edgar Link	pending
kalv-ex1021_555.htm	Edgar Link	pending
kalv-ex231_9.htm	Edgar Link	pending
kalv-ex311_11.htm	Edgar Link	pending
kalv-ex312_12.htm	Edgar Link	pending
kalv-ex321_10.htm	Edgar Link	pending
kalv-ex322_6.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KALV
KalVista Pharmaceuticals, Inc. Stock $kalv

2021 Q3 Form 10-K Financial Statement

#000156459021036441 Filed on July 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KALV KalVista Pharmaceuticals, Inc. Stock $kalv

2021 Q3 Form 10-K Financial Statement

#000156459021036441 Filed on July 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KALV
KalVista Pharmaceuticals, Inc. Stock $kalv